Business
Taysha Gene Therapies Expands Leadership Team to Deepen Manufacturing and Communications Capabilities
Greg Gara joins as SVP of Manufacturing, previously led the construction and commission of the AveXis Libertyville, Research Triangle Park and Longmont
About this update from Taysha Gene Therapies, Inc.
[{"type":"text","content":"\nGreg Gara joins as SVP of Manufacturing, previously led the construction and commission of the AveXis Libertyville, Research Triangle Park and Longmont manufacturing facilities \n\nKimberly Lee, D.O., joins as SVP of Corporate Communications and Investor Relations, brings over 20 years of capital markets and strategic corporate finance experience\n\n DALLAS--(BUSINESS WIRE)--\nTaysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system in both rare and large patient populations, today announced new additions to its leadership team with the appointments of Greg Gara as Senior Vice President of Manufacturing and Kimberly Lee, D.O., as Senior Vice President of Corporate Communications and Investor Relations.\n\n“We are excited to welcome Greg and Kim to Taysha’s leadership team,” said RA Session II, President, Founder and CEO of Taysha. “They each bring significant domain experience and their contributions will be invaluable as we continue our mission of eradicating monogenic CNS diseases. Greg’s technical expertise in AAV gene therapy manufacturing along with his proven success in constructing several cGMP gene therapy facilities and Kim’s deep experience across capital markets and corporate communications will add tremendous value to the team. Importantly, both share our unrelenting, patient-first focus and passion for bringing new cures to life.”\n\nMr. Gara has over 25 years of experience in designing, constructing, and starting up large- and small-scale manufacturing facilities for biotechnology companies globally. Prior to joining Taysha, he served as Vice President of Pharmaceutical Engineering at Sarepta, where he led and managed manufacturing operations for all gene therapy products. Before Sarepta, he served as Vice President of Technical Operations and Engineering at AveXis, a Novartis company, where he led the design, construction, and startup of the Libertyville facility and the new facilities in Research Triangle Park and Colorado. Mr. Gara also led the team for the facility expansion in North Carolina and the renovation of the Colorado site. Prior to AveXis, he led the facilities and engineering organization at Hospira prior to the company’s acquisition by P...